osm-1 Antibody

What is OSM and what role does it play in inflammatory responses?

Oncostatin M (OSM) is a pleiotropic cytokine involved in various inflammatory responses including wound healing, liver regeneration, and bone remodeling. It acts through specific receptor complexes to activate multiple signaling pathways, predominantly the JAK/STAT pathway leading to STAT1 and STAT3 phosphorylation . OSM functions as a key mediator in both acute and chronic inflammatory conditions, regulating extracellular matrix turnover, cell proliferation, and differentiation across multiple tissue types . Unlike related cytokines such as IL-31 or LIF, OSM demonstrates potent activation of inflammatory cascades, particularly in skin cells and fibroblasts, making it an important target for therapeutic intervention in inflammatory diseases .

What diseases are associated with OSM signaling pathways?

OSM signaling has been implicated in numerous inflammatory and autoimmune conditions across various organ systems. The clinical relevance of OSM extends to:

This extensive involvement across multiple disease states highlights the importance of OSM as a therapeutic target .

How does OSM-1 Antibody differ from other OSM-targeting antibodies?

OSM-1 Antibody refers to a class of monoclonal antibodies specifically designed to target either OSM directly or its receptor components. These antibodies can be distinguished by their targeting mechanism: direct OSM inhibition (like GSK2330811) versus receptor blockade (like KPL-716 which targets OSMRβ) . The mechanistic difference is significant as receptor-targeting antibodies may interfere with signaling from multiple ligands that share the same receptor component, while direct OSM targeting specifically neutralizes this cytokine's activity. Research suggests that receptor-targeted approaches may provide broader inhibition of inflammatory cascades, particularly in conditions where redundant cytokine signaling exists . The selection of antibody type depends on the specific research question and disease context.

What cellular models are most appropriate for studying OSM antibody efficacy?

Human epidermal keratinocytes (HEKs) and human dermal fibroblasts (HDFs) represent optimal cellular models for testing OSM antibody efficacy. These cell types demonstrate robust and reproducible responses to OSM stimulation through activation of STAT1 and STAT3 signaling pathways . When designing experiments:

• Both HEKs and HDFs show significant upregulation of monocyte chemoattractant protein-1 (MCP-1/CCL2) in response to OSM stimulation, making this a reliable readout for antibody efficacy testing .

• Western blot analysis of phosphorylated STAT1 and STAT3 provides a direct assessment of OSM signaling inhibition by test antibodies .

• Comparative studies should include related cytokines like leukemia inhibitory factor (LIF) and IL-31 as controls, as these cytokines show minimal activation of similar pathways in these cell types .

• Co-stimulation with IL-4 or IL-13 is recommended to assess the ability of antibodies to block synergistic inflammatory responses, which more closely mimic complex disease environments .

These cellular models have been validated across multiple studies and provide consistent, quantifiable responses for antibody screening and characterization .

What biomarkers should researchers measure to assess OSM antibody efficacy?

A multivariate approach to biomarker assessment provides the most comprehensive evaluation of OSM antibody efficacy. Based on clinical studies, four key biomarkers have been identified as particularly valuable:

• Alpha smooth muscle actin (αSMA) measured by skin histology - a direct indicator of myofibroblast activation and fibrotic processes .

• 2-gene skin score (2GSSC) derived from measurement of THBS1 and MS4A4A mRNA in skin samples - provides a genetic signature associated with OSM activity .

• Procollagen type III N-terminal peptide (PIIINP) measured in serum - reflects active collagen turnover and fibrotic processes .

• C-C motif chemokine ligand 2 (CCL2/MCP-1) measured by mRNA in skin or protein in supernatants - indicates inflammatory activation .

Additional pharmacodynamic biomarkers that should be considered include:

• Serum IL-6 and CRP levels - indicators of systemic inflammation

• Suppressor of cytokine signalling-3 (SOCS3) mRNA - reflects active JAK/STAT pathway signaling

• Phosphorylated STAT1 and STAT3 - direct indicators of OSM signaling activity

These markers were selected based on their established modulation by OSM, differentiation between disease and healthy populations, correlation with clinical endpoints, and response to therapies within experimental timeframes .

How should researchers approach target engagement studies for OSM antibodies?

Target engagement assessment is critical for interpreting the biological effects of OSM antibodies. A comprehensive approach should include:

• Measurement of both free and total OSM in blood and affected tissues to calculate percentage target engagement using the formula: [(1−free OSM/baseline OSM)*100] .

• Implementation of skin suction blister techniques for directly sampling interstitial fluid in skin, providing insights into antibody penetration and target engagement in affected tissues .

• Utilization of minimal physiologically based pharmacokinetic (mPBPK) modeling to integrate individual dosing information with measured parameters .

• Parallel assessment of downstream signaling markers like phosphorylated STAT proteins to confirm functional blockade corresponding to target engagement levels .

• Time-course studies to determine the relationship between antibody concentrations, target engagement, and biological responses .

The GSK2330811 clinical trial in systemic sclerosis demonstrated that despite evidence of target engagement in both serum and skin compartments, anticipated biological effects were not observed, highlighting the importance of comprehensive biomarker assessment beyond simple target engagement .

How should researchers interpret negative clinical findings despite evidence of target engagement?

The interpretation of negative clinical findings despite evidence of target engagement represents a complex challenge in OSM antibody research. The GSK2330811 study in systemic sclerosis provides an instructive case study where:

• Pharmacokinetic analyses confirmed that GSK2330811 reached expected plasma concentrations and demonstrated target engagement in serum .

• Skin blister fluid analysis, though limited, confirmed that the antibody reached the skin compartment .

• Despite this target engagement, the anticipated effects on biomarkers of inflammation and fibrosis were not observed .

This apparent contradiction should be interpreted by considering:

• Potential redundancy in inflammatory signaling pathways, where other cytokines (particularly IL-6) may compensate for OSM inhibition .

• The possibility that OSM blockade alone may be inadequate to ameliorate complex disease pathology that involves multiple inflammatory mediators .

• The timing of intervention relative to disease stage, as late-stage fibrotic processes may be less dependent on ongoing OSM signaling.

• The relationship between target engagement thresholds and biological effect, where partial engagement may be insufficient to produce measurable outcomes .

These findings underscore the importance of considering OSM within the broader context of inflammatory networks rather than as an isolated target .

What explains the synergistic effects between OSM and other cytokines like IL-4 and IL-13?

The synergistic interactions between OSM and Th2 cytokines (IL-4 and IL-13) represent a significant finding with implications for both understanding disease pathogenesis and designing therapeutic strategies. This synergy is characterized by:

• Markedly enhanced production of MCP-1/CCL2 when cells are stimulated with OSM in combination with either IL-4 or IL-13, compared to stimulation with individual cytokines .

• OSM significantly stimulates mRNA expression for type II IL-4 receptor components, potentially increasing cellular responsiveness to IL-4 and IL-13 .

• Different signaling pathway activation, with OSM primarily activating STAT1 and STAT3, while IL-13 activates STAT6, suggesting pathway convergence at downstream targets .

The molecular mechanisms underlying this synergy likely involve:

• Cross-regulation of receptor expression, enhancing sensitivity to both cytokine families

• Convergence of distinct signaling pathways on shared transcriptional targets

• Cooperative effects on chromatin remodeling, facilitating enhanced gene expression

• Potential formation of higher-order transcriptional complexes involving multiple activated STAT proteins

This synergy has important implications for diseases where both OSM and Th2 cytokines are elevated, suggesting that combination therapies targeting both pathways might be more effective than single-target approaches .

How can researchers distinguish between direct OSM inhibition effects and secondary pathway effects?

Distinguishing direct from indirect effects of OSM inhibition requires a systematic approach integrating multiple experimental techniques:

• Temporal analysis: Direct effects typically occur rapidly (minutes to hours) following antibody administration, while secondary effects emerge later (hours to days). Sequential sampling at defined intervals can help establish the sequence of events .

• Pathway-specific inhibition studies: Use of selective JAK inhibitors (e.g., tofacitinib for JAK1/3, baricitinib for JAK1/2) alongside OSM antibodies can help delineate which downstream effects depend on specific signaling nodes .

• Transcriptomic profiling: Comparison of gene expression changes induced by OSM stimulation versus those reversed by antibody treatment identifies direct transcriptional targets. This approach revealed that OSM significantly stimulates mRNA for type II IL-4 receptor and type II OSM receptor .

• Functional readouts with varying specificity: For example, while MCP-1/CCL2 production can be induced by multiple stimuli, the combined assessment of STAT phosphorylation patterns provides pathway specificity. OSM uniquely induces both pSTAT1 and pSTAT3 but not pSTAT6, while IL-13 selectively activates STAT6 .

• Genetic approaches: CRISPR-Cas9 targeting of specific components of the OSM signaling pathway can confirm which downstream effects depend on direct OSM signaling versus secondary pathways.

This multi-faceted approach provides a more complete picture of the cascade of events following OSM inhibition .

What safety considerations should be incorporated into OSM antibody research protocols?

Safety monitoring in OSM antibody research must address the specific on-target adverse events observed in clinical studies. The experience with GSK2330811 highlighted:

• Dose-dependent decreases in hemoglobin and platelet counts that were observed in the higher dose group (300 mg) but not in the lower dose group (100 mg) or placebo .

• These hematological effects were identified as on-target effects, suggesting a physiological role for OSM in regulating these parameters .

A comprehensive safety monitoring protocol should include:

• Regular complete blood count assessments with particular attention to hemoglobin levels and platelet counts

• Liver function testing, given OSM's role in liver biology

• Careful monitoring of infection rates, considering OSM's role in inflammatory responses

• Dose-escalation designs with interim safety analyses before proceeding to higher doses

• Consideration of distinct safety profiles at different doses, as demonstrated by the contrasting profiles of 100 mg versus 300 mg GSK2330811

• Extended follow-up periods to capture delayed adverse events

Researchers should also consider the potential for different safety profiles in various disease states, as the physiological role of OSM may vary by tissue and disease context .

How can OSM antibody specificity be optimized to target disease-specific pathways?

Optimizing antibody specificity for disease-specific OSM pathways represents an advanced approach to improve therapeutic efficacy while reducing off-target effects. Several strategies warrant consideration:

• Receptor subset targeting: Since OSM can signal through two distinct receptor complexes (type I: gp130/LIFR and type II: gp130/OSMRβ), developing antibodies specific to either complex might provide disease selectivity. Research indicates that OSM significantly stimulates mRNA for type II OSM receptor, suggesting this complex may be more relevant in certain inflammatory conditions .

• Epitope-specific targeting: Structural biology approaches can identify OSM epitopes specifically involved in disease-relevant interactions, allowing for the development of antibodies that block pathogenic signaling while preserving physiological functions.

• Tissue-specific delivery: Conjugating OSM antibodies with tissue-specific targeting moieties can enhance local concentration in affected tissues while minimizing systemic exposure and related adverse events like the hematological effects observed with GSK2330811 .

• Context-dependent activation: Developing antibodies that preferentially bind OSM under specific microenvironmental conditions (pH, protease activity) characteristic of disease states could enhance therapeutic index.

• Combination approaches: As demonstrated by the synergistic effects between OSM and IL-4/IL-13, combining OSM antibodies with inhibitors of synergistic pathways might allow for lower dosing and reduction of adverse effects while maintaining efficacy .

These approaches require advanced antibody engineering and comprehensive understanding of the molecular mechanisms underlying OSM's role in specific disease states .

What experimental models best predict clinical efficacy of OSM-targeting antibodies?

The translation of preclinical findings to clinical outcomes remains challenging for OSM-targeting therapies. Based on current research, several experimental models offer complementary insights:

• Human primary cell systems: Human epidermal keratinocytes and dermal fibroblasts demonstrated clear OSM-responsive phenotypes that were effectively inhibited by anti-OSMRβ antibody KPL-716 . These systems allow for detailed mechanistic studies of signaling and biomarker modulation.

• Ex vivo tissue explants: Patient-derived tissue samples maintain complex cellular architecture and can be used to assess antibody penetration, target engagement, and functional effects in a more physiologically relevant context than isolated cells.

• IBD mouse models: In vivo inflammatory bowel disease studies comparing wildtype and Osm-/- mice showed that lack of OSM signaling led to significant decreases in pathology, leukocyte infiltration, epithelial disruption, and disease severity . Such genetic models help validate the pathological role of OSM in specific conditions.

• Humanized mouse models: These allow for testing of human-specific antibodies against human OSM in vivo, providing information on pharmacokinetics, tissue distribution, and preliminary efficacy.

• Minimally invasive human sampling: The skin suction blister technique used in the GSK2330811 trial represents an innovative approach to directly assess target engagement and biomarker modulation in affected tissues .

Most importantly, the integration of biomarker analysis across these models, focusing on the four key markers (αSMA, 2GSSC, PIIINP, and CCL2) identified in clinical research, provides the strongest predictive framework for clinical translation .

What are the implications of OSM's role in anti-TNF therapy resistance for future combination therapies?

OSM's involvement in anti-TNF therapy resistance represents a significant opportunity for developing more effective combination approaches for inflammatory diseases. Research in inflammatory bowel disease has revealed:

• OSM and OSMR are overexpressed in many IBD lesions .

• Approximately one-third of patients do not respond to infliximab (anti-TNF) initially, and between 23% and 46% develop resistance within 12 months of treatment .

• A retrospective cohort study demonstrated that patients with increased levels of OSM had a lower chance of remaining in remission 1 year after starting anti-TNF therapies .

These findings suggest several strategic approaches for future research:

• Simultaneous targeting of both TNF and OSM pathways may overcome primary and acquired resistance to anti-TNF monotherapy.

• OSM levels could serve as a biomarker to stratify patients for combination therapy versus anti-TNF monotherapy.

• Sequential therapy approaches, with anti-OSM treatment reserved for patients who demonstrate inadequate response to anti-TNF, might optimize therapeutic outcomes while minimizing unnecessary exposure.

• Mechanistic studies are needed to elucidate how OSM signaling circumvents TNF blockade, potentially revealing additional therapeutic targets.

The design of clinical trials incorporating both anti-OSM and anti-TNF agents should carefully consider the timing of interventions and include comprehensive biomarker assessments to identify patterns of response .

How might OSM antibody research inform the broader field of cytokine-targeting therapeutics?

The research journey with OSM-targeting antibodies provides valuable lessons for the broader field of cytokine-targeting therapeutics:

• Importance of pathway redundancy: Despite robust target engagement, GSK2330811 did not modulate expected biomarkers of inflammation or fibrosis in systemic sclerosis patients, highlighting how redundant cytokine pathways (particularly IL-6) may compensate for single-cytokine blockade .

• Synergistic interactions between cytokine families: The discovery that OSM synergizes with IL-4 and IL-13 to dramatically enhance MCP-1/CCL2 production suggests that understanding cytokine networks, rather than individual cytokines in isolation, is crucial for effective therapeutic design .

• Biomarker-guided development: The identification and validation of four key biomarkers (αSMA, 2GSSC, PIIINP, and CCL2) for OSM pathway activity demonstrates how a multivariate biomarker approach can provide a more robust assessment of target engagement and biological effect than any single marker .

• Innovative clinical trial design: The incorporation of skin suction blisters and home FVC measurements in the GSK2330811 trial exemplifies how novel techniques can enhance the assessment of target engagement and efficacy in difficult-to-study conditions .

• Dose-dependent safety profiles: The contrasting safety profiles between 100 mg and 300 mg doses of GSK2330811 underscores the importance of careful dose-finding studies and the possibility that optimal therapeutic indices may exist at intermediate doses .

These insights can guide more efficient development of other cytokine-targeting therapies, potentially reducing late-stage clinical trial failures and accelerating the delivery of effective treatments to patients .